Autres langues Sangamo Therapeutics, Inc.

Actions

SGMO

US8006771062

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,5558 ^USD	+6,48%		+7,34%	+2,30%

22/03	Sangamo Therapeutics fixe le prix de son offre directe enregistrée à 24 millions de dollars	MT
14/03	Sangamo Therapeutics pousse les programmes de neurologie vers le développement clinique, selon Wedbush	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast	02/05
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data from Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting	23/04
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)	22/04
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	25/03
Sangamo Therapeutics Prices $24 Million Registered Direct Offering	22/03
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	22/03
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	14/03
Sangamo: Q4 Earnings Snapshot	13/03
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	13/03
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs	13/03
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023	13/03
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps	13/03
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast	12/03
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease	12/02
Sangamo Therapeutics Says Early Phase 1/2 Data Shows 'Durable' Safety, Efficacy of Fabry Disease Drug Candidate	06/02
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile	06/02
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920	05/02
Vaxcyte Names Chief People Officer	16/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Sangamo Therapeutics, Inc.

Actions

SGMO

US8006771062

Autres langues

Filtres